Suppr超能文献

术前给予氢化可的松与安慰剂对比对无肾上腺功能不全的患者行内镜经蝶窦切除无功能垂体腺瘤术中皮质醇水平的影响:一项双盲随机试验

Comparison of intraoperative cortisol levels after preoperative hydrocortisone administration versus placebo in patients without adrenal insufficiency undergoing endoscopic transsphenoidal removal of nonfunctioning pituitary adenomas: a double-blind randomized trial.

作者信息

Lee Hyung-Chul, Yoon Hyun-Kyu, Kim Jung Hee, Kim Yong Hwy, Park Hee-Pyoung

机构信息

Departments of1Anesthesiology and Pain Medicine.

2Medicine, and.

出版信息

J Neurosurg. 2020 Jan 24;134(2):526-534. doi: 10.3171/2019.11.JNS192381. Print 2021 Feb 1.

Abstract

OBJECTIVE

In this double-blind randomized trial, the necessity of preoperative steroid administration in patients without adrenal insufficiency (AI) undergoing endoscopic transsphenoidal surgery (ETSS) for pituitary adenoma was evaluated.

METHODS

Forty patients with and without AI, defined as a peak cortisol level > 18 µg/dl on the insulin tolerance test or rapid adrenocorticotropic hormone (ACTH) test, undergoing ETSS for nonfunctioning pituitary adenomas were randomly allocated to treatment with either 100 mg of preoperative hydrocortisone (group HC, n = 20) or normal saline (group C, n = 20). The patients with pituitary apoplexy, the use of a drug within the last 3 months that could affect the hypothalamic-pituitary-adrenal axis, or a previous history of brain or adrenal surgery were excluded. Intraoperative cortisol and ACTH levels were measured after anesthesia induction, dura incision, and tumor removal, and at the end of surgery. Intraoperative hypotension, early postoperative AI, and postoperative 3-month pituitary function were investigated.

RESULTS

Intraoperative serum cortisol levels were significantly higher in the HC group than in the C group after anesthesia induction (median 69.0 µg/dl [IQR 62.2-89.6 µg/dl] vs 12.7 µg/dl [IQR 8.4-18.2 µg/dl], median difference 57.5 µg/dl [95% CI 33.0-172.9 µg/dl]), after dura incision (median 53.2 µg/dl [IQR 44.9-63.8 µg/dl] vs 6.4 [IQR 4.8-9.2 µg/dl], median difference 46.6 µg/dl [95% CI 13.3-89.2 µg/dl]), after tumor removal (median 49.5 µg/dl [IQR 43.6-62.4 µg/dl] vs 9.2 µg/dl [IQR 5.75-16.7 µg/dl], median difference 39.4 µg/dl [95% CI 0.3-78.1 µg/dl]), and at the end of surgery (median 46.9 µg/dl [IQR 40.1-63.4 µg/dl] vs 16.9 µg/dl [IQR 12.1-23.2 µg/dl], median difference 32.2 µg/dl [95% CI -42.0 to 228.1 µg/dl]). Serum ACTH levels were significantly lower in group HC than in group C after anesthesia induction (median 3.9 pmol/L [IQR 1.7-5.2 pmol/L] vs 6.9 pmol/L [IQR 3.9-11.9 pmol/L], p = 0.007). No patient showed intraoperative hypotension due to AI. Early postoperative AI was observed in 3 and 5 patients in groups HC and C, respectively. The postoperative 3-month pituitary hormone outcomes including ACTH deficiency were not different between groups.

CONCLUSIONS

Preoperative steroid administration may be unnecessary in patients without AI undergoing ETSS for nonfunctioning pituitary adenomas. However, a further large-scale study is needed to determine whether preoperative steroid administration has a significant impact on clinically meaningful events such as perioperative AI and postoperative 3-month ACTH deficiency in these patients.Korean Clinical Trial Registry no.: KCT0002426 (https://cris.nih.go.kr/cris/).

摘要

目的

在这项双盲随机试验中,评估了在无肾上腺功能不全(AI)的垂体腺瘤患者接受内镜经蝶窦手术(ETSS)时术前给予类固醇的必要性。

方法

40例因无功能垂体腺瘤接受ETSS的患者,根据胰岛素耐量试验或快速促肾上腺皮质激素(ACTH)试验中皮质醇峰值水平>18μg/dl定义有无AI,被随机分为两组,分别接受100mg术前氢化可的松治疗(HC组,n = 20)或生理盐水治疗(C组,n = 20)。排除垂体卒中患者、过去3个月内使用过可能影响下丘脑 - 垂体 - 肾上腺轴的药物的患者或有脑或肾上腺手术史的患者。在麻醉诱导后、硬脑膜切开后、肿瘤切除后及手术结束时测量术中皮质醇和ACTH水平。调查术中低血压、术后早期AI及术后3个月的垂体功能。

结果

麻醉诱导后,HC组术中血清皮质醇水平显著高于C组(中位数69.0μg/dl [四分位间距62.2 - 89.6μg/dl] 对比12.7μg/dl [四分位间距8.4 - 18.2μg/dl],中位数差异57.5μg/dl [95%可信区间33.0 - 172.9μg/dl]),硬脑膜切开后(中位数53.2μg/dl [四分位间距44.9 - 63.8μg/dl] 对比6.4 [四分位间距4.8 - 9.2μg/dl],中位数差异46.6μg/dl [95%可信区间13.3 - 89.2μg/dl]),肿瘤切除后(中位数49.5μg/dl [四分位间距43.6 - 62.4μg/dl] 对比9.2μg/dl [四分位间距5.75 - 16.7μg/dl],中位数差异39.4μg/dl [95%可信区间0.3 - 78.1μg/dl]),及手术结束时(中位数46.9μg/dl [四分位间距40.1 - 63.4μg/dl] 对比16.9μg/dl [四分位间距12.1 - 23.2μg/dl],中位数差异32.2μg/dl [95%可信区间 - 42.0至228.1μg/dl])。麻醉诱导后,HC组血清ACTH水平显著低于C组(中位数3.9pmol/L [四分位间距1.7 - 5.2pmol/L] 对比6.9pmol/L [四分位间距3.9 - 11.9pmol/L],p = 0.007)。没有患者因AI出现术中低血压。HC组和C组分别有3例和5例患者出现术后早期AI。两组术后3个月包括ACTH缺乏在内的垂体激素结果无差异。

结论

对于无AI的垂体腺瘤患者接受ETSS,术前给予类固醇可能不必要。然而,需要进一步的大规模研究来确定术前给予类固醇是否对这些患者围手术期AI和术后3个月ACTH缺乏等具有临床意义的事件有显著影响。韩国临床试验注册号:KCT0002426(https://cris.nih.go.kr/cris/)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验